Country: Armenia
Language: English
Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
paracetamol, caffeine, codeine (codeine phosphate)
GlaxoSmithKline Dungarvan Limited
N02BE51
paracetamol, caffeine, codeine (codeine phosphate)
500mg+30mg+8mg
tablets soluble
(12/6x2/) strips
Prescription
Registered
2017-05-30
SUMMARYOFPRODUCTCHARACTERISTICS _ _ 1. NAME OFTHE MEDICINAL PRODUCT _ _ SolpadeineSolubleTablets _ _ 2. QUALITATIVE AND QUANTITATIVE COMPOSITION _ _ Each tablet contains Paracetamol PhEur500 mg, Codeine Phosphate HemyhydratePhEur8 mgand CaffeinePhEur30.0 mg. _ _ 3. PHARMACEUTICAL FORM _ _ Solubletablets _ _ Whiteflattabletswithbevelsmoothononesideandwithscorelineontheother side. _ _ _ _ 4. CLINICAL PARTICULARS _ _ 4.1. THERAPEUTICINDICATIONS _ _ Solpadeinesoluble tablets arerecommended forthe relief of acutemoderate pain, including:headache, migraine, toothache (pain afterdental procedures/ tooth extraction), musculoskeletal pain, neuralgia,dysmenorrhoea, sciatica, pain associated with sinusitis and sorethroat. Relief ofpain associated with fever. _ _ 4.2. POSOLOGY ANDMETHOD OFADMINISTRATION _ _ _ _ Adultsaged18years andover(includingtheelderly): _ _ Dissolve1-2 tablets in ahalf tumblerof water. Take every4-6 hours as required. Minimum dosinginterval: 4 hours. Maximum single doseis2 tablets. Maximumdailydoseis 8 tablets. _ _ _ _ Medicineshould not be taken morethan 3 days without consulting yourdoctor. Do not exceed the recommended dose. Should not beusedwith other paracetamol or codeine containing products. _ _ 4.3. CONTRAINDICATIONS Paracetamol-caffeine-codeine is contraindicated in patients: _ _ _ _ With a previous historyof hypersensitivityto paracetamol, caffeine, codeine, opioid analgesics or any of excipients under theageof 18years becauseof therisk of opioid toxicitydueto the variable and unpredictable metabolism of codeine to morphine _ _ who arebreastfeeding whoareknowntobeCYP2D6ultra-rapidmetabolisers.Ifthepatientis anextensiveorultra-rapidCYP2D6 metaboliser thereis an increased risk ofdevelopingsymptomsofopioidtoxicity,evenatcommonlyprescribed doses.General symptoms of opioid toxicityinclude confusion, somnolence, shallow breathing, small pupils, nausea, vomiting, constipation and lack of appetite. In severe cases this mayincludesymptoms of circulatoryand respiratory depression which m Read the complete document